$CCEL
CRYO CELL INTERNATIONAL INC

2014 Q4 Form 10-K Financial Statement

#000119312516485790 Filed on February 29, 2016

View on sec.gov

Income Statement

Concept 2014 Q4 2014 2013 Q4
Revenue $4.980M $20.13M $4.710M
YoY Change 5.73% 5.96% -2.28%
Cost Of Revenue $1.310M $5.632M $1.310M
YoY Change 0.0% 5.82% -1.5%
Gross Profit $3.670M $14.49M $3.400M
YoY Change 7.94% 6.01% -2.86%
Gross Profit Margin 73.69% 72.02% 72.19%
Selling, General & Admin $3.430M $12.25M $2.880M
YoY Change 19.1% 7.79% -26.53%
% of Gross Profit 93.46% 84.53% 84.71%
Research & Development $10.00K $64.37K $10.00K
YoY Change 0.0% 77.97% -50.0%
% of Gross Profit 0.27% 0.44% 0.29%
Depreciation & Amortization $90.00K $375.0K $90.00K
YoY Change 0.0% -1.06% -43.75%
% of Gross Profit 2.45% 2.59% 2.65%
Operating Expenses $3.480M $12.32M $2.930M
YoY Change 18.77% 8.01% -26.57%
Operating Profit $190.0K $1.981M $470.0K
YoY Change -59.57% 16.35% -195.92%
Interest Expense -$440.0K $1.151M -$610.0K
YoY Change -27.87% -17.79% 117.86%
% of Operating Profit -231.58% 58.12% -129.79%
Other Income/Expense, Net -$20.00K -$941.2K $20.00K
YoY Change -200.0% -30.37% 100.0%
Pretax Income -$270.0K $677.1K -$130.0K
YoY Change 107.69% 243.7% -83.95%
Income Tax $30.00K $123.5K $40.00K
% Of Pretax Income 18.24%
Net Earnings -$300.0K $553.6K -$170.0K
YoY Change 76.47% 1917.87% -80.0%
Net Earnings / Revenue -6.02% 2.75% -3.61%
Basic Earnings Per Share $0.05
Diluted Earnings Per Share -$30.80K $0.05 -$15.50K
COMMON SHARES
Basic Shares Outstanding 9.756M shares 10.18M shares 10.76M shares
Diluted Shares Outstanding 10.43M shares

Balance Sheet

Concept 2014 Q4 2014 2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.380M $3.382M $3.960M
YoY Change -14.65% -13.95% 47.76%
Cash & Equivalents $3.279M $3.279M $3.925M
Short-Term Investments $100.0K $102.7K $40.00K
Other Short-Term Assets $59.38K $1.038M $155.0K
YoY Change -61.68% -35.53% -95.22%
Inventory $63.74K $0.00
Prepaid Expenses $710.8K $490.0K
Receivables $4.072M $4.072M $3.336M
Other Receivables $0.00 $0.00 $550.0K
Total Short-Term Assets $8.492M $8.492M $9.463M
YoY Change -10.27% -9.95% 1.59%
LONG-TERM ASSETS
Property, Plant & Equipment $953.4K $953.4K $1.207M
YoY Change -21.03% -21.2% -5.76%
Goodwill $0.00
YoY Change
Intangibles $28.36K
YoY Change
Long-Term Investments $684.0K $0.00 $684.0K
YoY Change 0.0% -100.0% -2.29%
Other Assets $764.2K $51.85K $830.1K
YoY Change -7.94% -42.39% -52.14%
Total Long-Term Assets $1.718M $1.718M $2.037M
YoY Change -15.69% -17.02% -32.44%
TOTAL ASSETS
Total Short-Term Assets $8.492M $8.492M $9.463M
Total Long-Term Assets $1.718M $1.718M $2.037M
Total Assets $10.21M $10.21M $11.50M
YoY Change -11.23% -11.22% -6.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $992.9K $992.9K $1.195M
YoY Change -16.9% -16.56% -1.25%
Accrued Expenses $1.472M $1.472M $1.801M
YoY Change -18.28% -18.24% -38.28%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $9.127M $9.127M $9.810M
YoY Change -6.96% -6.96% -8.0%
LONG-TERM LIABILITIES
Long-Term Debt $2.300M $0.00 $2.300M
YoY Change 0.0% 0.0%
Other Long-Term Liabilities $11.81M $11.81M $10.96M
YoY Change 7.76% 7.75% 2.76%
Total Long-Term Liabilities $14.11M $11.81M $13.26M
YoY Change 6.42% 7.75% 2.27%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.127M $9.127M $9.810M
Total Long-Term Liabilities $14.11M $11.81M $13.26M
Total Liabilities $23.24M $20.94M $23.07M
YoY Change 0.73% 0.8% -2.37%
SHAREHOLDERS EQUITY
Retained Earnings -$33.58M -$33.73M
YoY Change -0.45% -0.08%
Common Stock $27.96M $27.38M
YoY Change 2.11% 22989.41%
Preferred Stock
YoY Change
Treasury Stock (at cost) $5.113M $2.926M
YoY Change 74.72% 33.77%
Treasury Stock Shares
Shareholders Equity -$10.73M -$10.73M -$9.268M
YoY Change
Total Liabilities & Shareholders Equity $10.21M $10.21M $11.50M
YoY Change -11.23% -11.22% -6.73%

Cashflow Statement

Concept 2014 Q4 2014 2013 Q4
OPERATING ACTIVITIES
Net Income -$300.0K $553.6K -$170.0K
YoY Change 76.47% 1917.87% -80.0%
Depreciation, Depletion And Amortization $90.00K $375.0K $90.00K
YoY Change 0.0% -1.06% -43.75%
Cash From Operating Activities $240.0K $1.555M -$20.00K
YoY Change -1300.0% 89.16% -106.25%
INVESTING ACTIVITIES
Capital Expenditures -$30.00K $120.5K -$130.0K
YoY Change -76.92% -65.55%
Acquisitions
YoY Change
Other Investing Activities -$20.00K $511.7K $410.0K
YoY Change -104.88% -66.99% 485.71%
Cash From Investing Activities -$50.00K $391.2K $290.0K
YoY Change -117.24% -65.97% 314.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.671M
YoY Change 261.63%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -370.0K -2.592M -60.00K
YoY Change 516.67% 258.16% -86.05%
NET CHANGE
Cash From Operating Activities 240.0K 1.555M -20.00K
Cash From Investing Activities -50.00K 391.2K 290.0K
Cash From Financing Activities -370.0K -2.592M -60.00K
Net Change In Cash -180.0K -645.9K 210.0K
YoY Change -185.71% -151.76% -625.0%
FREE CASH FLOW
Cash From Operating Activities $240.0K $1.555M -$20.00K
Capital Expenditures -$30.00K $120.5K -$130.0K
Free Cash Flow $270.0K $1.434M $110.0K
YoY Change 145.45% 203.75% -65.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2014Q4 us-gaap Treasury Stock Number Of Shares Held
TreasuryStockNumberOfSharesHeld
2215111 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11921285 shares
CY2011Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
1000000 shares
CY2013Q2 ccel Operating Lease Property Leased Area Covered Under Amended Agreement
OperatingLeasePropertyLeasedAreaCoveredUnderAmendedAgreement
9600 sqft
CY2016Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8960337 shares
CY2012Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
3000000 shares
CY2011Q3 ccel Restricted Cash Transferred To Trust
RestrictedCashTransferredToTrust
2500000
CY2015Q2 dei Entity Public Float
EntityPublicFloat
15737020
CY2009Q4 ccel Payment For Sponsor Fees
PaymentForSponsorFees
100000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-9267985
CY2013Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1994575
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3925156
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
27083 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.64
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9706174 shares
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
27842106
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
-10726663
CY2014Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2300000
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
11809088
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
25661
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6662552
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
992910
CY2014Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1976966
CY2014Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
612043
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1471699
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-33575334
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10209586
CY2014Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
9509088
CY2015Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
2.17
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
119213
CY2014Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5919277
CY2014Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
430020
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9127161
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
10517000
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Interest Payable Current
InterestPayableCurrent
403975
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
49000
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
10517000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
764212
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
1066000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
391000
CY2014Q4 us-gaap Assets
Assets
10209586
CY2014Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
4151000
CY2014Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
28358
CY2014Q4 us-gaap Inventory Net
InventoryNet
63742
CY2014Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4071997
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
953415
CY2014Q4 us-gaap Treasury Stock Value
TreasuryStockValue
5112648
CY2014Q4 us-gaap Assets Current
AssetsCurrent
8491959
CY2014Q4 us-gaap Other Assets Current
OtherAssetsCurrent
59384
CY2014Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
102674
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
204141
CY2014Q4 us-gaap Equity Method Investments
EquityMethodInvestments
684000
CY2014Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
28358
CY2014Q4 us-gaap Goodwill
Goodwill
0
CY2014Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
710754
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3279267
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6872692
CY2014Q4 ccel Unamortized Sponsor Fees
UnamortizedSponsorFees
7000
CY2014Q4 ccel Deposits And Other Assets
DepositsAndOtherAssets
51854
CY2014Q4 ccel Deferred Tax Asset Net Operating Loss Credits And Other Carry Forward
DeferredTaxAssetNetOperatingLossCreditsAndOtherCarryForward
2260000
CY2014Q4 ccel Reserves Recorded Under Programs
ReservesRecordedUnderPrograms
17000
CY2014Q4 ccel Deferred Tax Asset From Unconsolidated Affiliate
DeferredTaxAssetFromUnconsolidatedAffiliate
1417000
CY2014Q4 ccel Deferred Tax Assets Tax Revenue Sharing Agreements Buy Out
DeferredTaxAssetsTaxRevenueSharingAgreementsBuyOut
1018000
CY2014Q4 ccel Deferred Tax Assets Tax Deferred Expense Depreciation And Amortization
DeferredTaxAssetsTaxDeferredExpenseDepreciationAndAmortization
165000
CY2014Q4 ccel Inventory Collection Kits
InventoryCollectionKits
63742
CY2015Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
953927 shares
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2015Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
2.16
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
15003 shares
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
1063000
CY2015Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
200000
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.90
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9010322 shares
CY2015Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
968930 shares
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12260340 shares
CY2015Q4 us-gaap Preferred Stock Redemption Price Per Share
PreferredStockRedemptionPricePerShare
0.01
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
193600
CY2015Q4 us-gaap Notes Payable Current
NotesPayableCurrent
307420
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
55000
CY2015Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
9041
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
10000000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
8265748
CY2015Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
820268
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2005351
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-25468991
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19497946
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Treasury Stock Number Of Shares Held
TreasuryStockNumberOfSharesHeld
3249790 shares
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
196165
CY2015Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
307420
CY2015Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
223490
CY2015Q4 us-gaap Deferred Tax Liabilities Investments
DeferredTaxLiabilitiesInvestments
103000
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
28530368
CY2015Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
323148
CY2015Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
868947
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-4964171
CY2015Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2300000
CY2015Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
339681
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
14038165
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
61971
CY2015Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
206118
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6782562
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1328619
CY2015Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2067130
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
10869218
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
122603
CY2015Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
103000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
16133
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6133952
CY2015Q4 us-gaap Notes Payable
NotesPayable
1176367
CY2015Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
302676
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10423952
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2630000
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
169932
CY2015Q4 us-gaap Interest Payable Current
InterestPayableCurrent
820436
CY2015Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
7267000
CY2015Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
610424
CY2015Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
282152
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
204344
CY2015Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
516328
CY2015Q4 us-gaap Goodwill
Goodwill
1777822
CY2015Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
134727
CY2015Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
427819
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4152162
CY2015Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
5930987
CY2015Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
52663
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7013022
CY2015Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
1336000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
618000
CY2015Q4 us-gaap Assets
Assets
19497946
CY2015Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
52663
CY2015Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
52663
CY2015Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
4624000
CY2015Q4 us-gaap Cash Collateral For Borrowed Securities
CashCollateralForBorrowedSecurities
200000
CY2015Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
516328
CY2015Q4 us-gaap Inventory Net
InventoryNet
475608
CY2015Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3058379
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
879070
CY2015Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
52663
CY2015Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
52663
CY2015Q4 us-gaap Treasury Stock Value
TreasuryStockValue
8318083
CY2015Q4 us-gaap Assets Current
AssetsCurrent
10353128
CY2015Q4 us-gaap Other Assets Current
OtherAssetsCurrent
88392
CY2015Q4 ccel Number Of Employee Stock Based Compensation Plan
NumberOfEmployeeStockBasedCompensationPlan
3 CompensationPlan
CY2015Q4 ccel Unamortized Sponsor Fees
UnamortizedSponsorFees
0
CY2015Q4 ccel Deposits And Other Assets
DepositsAndOtherAssets
40611
CY2015Q4 ccel Deferred Tax Asset Net Operating Loss Credits And Other Carry Forward
DeferredTaxAssetNetOperatingLossCreditsAndOtherCarryForward
1137000
CY2015Q4 ccel Reserves Recorded Under Programs
ReservesRecordedUnderPrograms
17000
CY2015Q4 ccel Deferred Tax Asset From Unconsolidated Affiliate
DeferredTaxAssetFromUnconsolidatedAffiliate
1686000
CY2015Q4 ccel Deferred Tax Assets Tax Revenue Sharing Agreements Buy Out
DeferredTaxAssetsTaxRevenueSharingAgreementsBuyOut
810000
CY2015Q4 ccel Finite Lived Intangible Assets Amortization Expense Thereafter
FiniteLivedIntangibleAssetsAmortizationExpenseThereafter
253013
CY2015Q4 ccel Deferred Tax Assets Tax Deferred Expense Depreciation And Amortization
DeferredTaxAssetsTaxDeferredExpenseDepreciationAndAmortization
7000
CY2015Q4 ccel Inventory Collection Kits
InventoryCollectionKits
57406
CY2006Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
11032
CY2006Q2 ccel Date Of Additional Operating Lease
DateOfAdditionalOperatingLease
2006-08-01
CY2006Q2 ccel Maximum Amount Of Lease Rental Expense For Additional Space Under Lease Term
MaximumAmountOfLeaseRentalExpenseForAdditionalSpaceUnderLeaseTerm
13176
CY2006Q2 ccel Termination Period Of Operating Lease
TerminationPeriodOfOperatingLease
2013
CY2006Q2 ccel Operating Lease Area Of Facility
OperatingLeaseAreaOfFacility
17600 sqft
CY2012Q1 ccel Increased Payment Warranty
IncreasedPaymentWarranty
75000
CY2012Q1 ccel Additional Payment Warranty
AdditionalPaymentWarranty
10000
ccel Minimum Percentage Probability Of Realized Tax Benefit On Settlement
MinimumPercentageProbabilityOfRealizedTaxBenefitOnSettlement
0.50 pure
CY2014 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.05
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.151 pure
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
120517
CY2014 us-gaap Net Income Loss
NetIncomeLoss
553623
CY2014 us-gaap Allowance For Doubtful Accounts Receivable Recoveries
AllowanceForDoubtfulAccountsReceivableRecoveries
346754
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
79142
CY2014 us-gaap Revenues
Revenues
20126546
CY2013Q2 ccel Lease Agreement Termination Fee
LeaseAgreementTerminationFee
150000
CY2013Q2 ccel Extended Operating Lease Area Of Facility
ExtendedOperatingLeaseAreaOfFacility
17600 sqft
CY2015Q2 ccel Tender Offer To Purchase Common Stock Price Per Share
TenderOfferToPurchaseCommonStockPricePerShare
3.25
CY2015Q2 ccel Percentage Of Outstanding Common Shares Purchases Under Tender Offer
PercentageOfOutstandingCommonSharesPurchasesUnderTenderOffer
0.0776 pure
CY2015Q2 ccel Tender Offer Sales Price
TenderOfferSalesPrice
2.29
CY2004Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
141000
CY2004Q2 ccel Operating Lease Period
OperatingLeasePeriod
P10Y
CY2004Q2 ccel Operating Lease Area Of Facility
OperatingLeaseAreaOfFacility
17600 sqft
CY2005Q4 ccel Payment Warranty
PaymentWarranty
50000
CY2014 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.05
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
1554821
CY2014 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.000 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.377 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.036 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Foreign
EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
0.155 pure
CY2014 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10429035 shares
CY2014 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
253229 shares
CY2014 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10175806 shares
CY2014 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
64764
CY2014 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2671060
CY2014 us-gaap License And Services Revenue
LicenseAndServicesRevenue
0
CY2014 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
18655060
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
1981234
CY2014 us-gaap Licenses Revenue
LicensesRevenue
1471486
CY2014 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
210258
CY2014 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-941201
CY2014 us-gaap Income Tax Reconciliation Tax Credits Foreign
IncomeTaxReconciliationTaxCreditsForeign
124000
CY2014 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2038973
CY2014 us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
187500
CY2014 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-31858
CY2014 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
220769
CY2014 us-gaap Increase Decrease In Notes Receivables
IncreaseDecreaseInNotesReceivables
-550782
CY2014 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-763989
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
553623
CY2014 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0
CY2014 ccel Effective Income Tax Rate Reconciliation Valuation Allowances
EffectiveIncomeTaxRateReconciliationValuationAllowances
0.000 pure
CY2014 ccel Income Tax Reconciliation Permanent Disallowances
IncomeTaxReconciliationPermanentDisallowances
123000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
677149
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
498137
CY2014 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-362884
CY2014 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1040033
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
123526
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
404233
CY2014 us-gaap Noncash Or Part Noncash Acquisition Investments Acquired1
NoncashOrPartNoncashAcquisitionInvestmentsAcquired1
81480
CY2014 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
123000
CY2014 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
698489
CY2014 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
0
CY2014 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
256546
CY2014 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
2671060
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-645889
CY2014 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0
CY2014 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-301000
CY2014 us-gaap Interest Expense
InterestExpense
1151459
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
391208
CY2014 us-gaap Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
206000
CY2014 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2014 us-gaap Costs And Expenses
CostsAndExpenses
18145312
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-2591918
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
64367
CY2014 us-gaap Cost Of Services
CostOfServices
5632041
CY2014 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
1667799
CY2014 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-329112
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
79142
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
404000
CY2014 us-gaap Advertising Expense
AdvertisingExpense
621000
CY2014 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2014 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
123000
CY2014 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
272000
CY2014 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
12251921
CY2014 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
28000
CY2014 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
25649
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-201915
CY2014 us-gaap Adjustment For Amortization
AdjustmentForAmortization
377008
CY2014 us-gaap Depreciation And Amortization
DepreciationAndAmortization
171334
CY2014 us-gaap Sponsor Fees
SponsorFees
20000
CY2014 us-gaap Depreciation
Depreciation
375000
CY2014 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1303436
CY2014 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
29000
CY2014 ccel Process And Storage Royalties
ProcessAndStorageRoyalties
1471486
CY2014 ccel Income Tax Reconciliation Foreign Tax Withholding
IncomeTaxReconciliationForeignTaxWithholding
124000
CY2014 ccel Payment To Participants Of Profit Sharing Agreement
PaymentToParticipantsOfProfitSharingAgreement
1926980
CY2014 ccel Defined Contribution Plan Employer Matching Contribution Amount
DefinedContributionPlanEmployerMatchingContributionAmount
107000
CY2014 ccel Effective Income Tax Rate Reconciliation Permanent Disallowances
EffectiveIncomeTaxRateReconciliationPermanentDisallowances
0.152 pure
CY2014 ccel Treasury Stock From Affiliates
TreasuryStockFromAffiliates
81480
CY2014 ccel Period For Doubtful Of Accounts Receivable Due From Client
PeriodForDoubtfulOfAccountsReceivableDueFromClient
P21Y
CY2014 ccel Effective Income Tax Rate Foreign Tax Withholding
EffectiveIncomeTaxRateForeignTaxWithholding
0.155 pure
CY2014 ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
-37628
CY2014 ccel Income Tax Reconciliation Valuation Allowance Release
IncomeTaxReconciliationValuationAllowanceRelease
0
CY2015 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2015 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.83
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
4851462
CY2015 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
3249790 shares
CY2015 us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Product Warranty and Cryo-Cell Cares<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">TM</sup> Program</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"> In December&#xA0;2005, the Company began providing its customers that enrolled after December&#xA0;2005 a payment warranty under which the Company agrees to pay $50,000 to its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various restrictions.&#xA0;Effective February&#xA0;1, 2012, the Company increased the $50,000 payment warranty to a $75,000 payment warranty to all of its new clients.&#xA0;Additionally, under the Cryo-Cell Cares<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">TM</sup> program, the Company will pay $10,000 to the client to offset personal expenses if the umbilical cord blood product is used for bone marrow reconstitution in a myeloblative transplant procedure. The product warranty and the Cryo-Cell Cares program are available to clients who enroll under this structure for as long as the specimen is stored with the Company. The Company has not experienced any claims under the warranty program nor has it incurred costs related to these warranties. The Company does not maintain insurance for this warranty program and therefore maintains reserves to cover any estimated potential liabilities. The Company&#x2019;s reserve balance is based on the $75,000 or $50,000 (as applicable) maximum payment and the $10,000 maximum expense reimbursement multiplied by formulas to determine the projected number of units requiring a payout. The Company determined the estimated expected usage and engraftment failure rates based on an analysis of the historical usage and failure rates and the historical usage and failure rates in other private and public cord blood banks based on published data. The Company&#x2019;s estimates of expected usage and engraftment failure could change as a result of changes in actual usage rates or failure rates and such changes would require an adjustment to the established reserves. The historical usage and failure rates have been very low and a small increase in the number of transplants or engraftment failures could cause a significant increase in the estimated rates used in determining the Company&#x2019;s reserve. In addition, the reserve will increase as additional umbilical cord blood specimens are stored which are subject to the warranty. As of November&#xA0;30, 2015 and November&#xA0;30, 2014 the Company recorded reserves under these programs in the amounts of approximately $17,000 and $17,000, respectively, which are included in accrued expenses in the accompanying consolidated balance sheets.</p> </div>
CY2015 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.336 pure
CY2015 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2015 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
2.56
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
22500 shares
CY2015 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015 dei Amendment Flag
AmendmentFlag
false
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P20D
CY2015 dei Document Type
DocumentType
10-K
CY2015 dei Entity Central Index Key
EntityCentralIndexKey
0000862692
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
0 shares
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
34580 shares
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
One Common Share per Right
CY2015 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Concentration of Risks</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"> Financial instruments that potentially subject the Company to concentrations of credit risk are principally cash and cash equivalent accounts in financial institutions, which often exceed the Federal Depository Insurance (FDIC) limit.&#xA0;The Company places its cash with high quality financial institutions and believes it is not exposed to any significant credit risk.&#xA0;The Company may from time to time invest some of its cash funds in certificates of deposit and bond investments maintained by brokers who are insured under the Securities Investor Protection Corporation (SIPC).&#xA0;The Company believes these are conservative investments with a low risk for any loss of principal.&#xA0;The Company regularly assesses its marketable security investments for impairment and adjusts its investment strategy as it deems appropriate.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 8%"> The Company depends on one supplier for the source of its collection kits, a critical component of the umbilical cord blood stem cell collection process.&#xA0;However, the Company believes that alternative sources of supply are available.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"> The Company depends on three suppliers for the supply and manufacturing of the Prepacyte CB units.&#xA0;However, the Company believes that alternative sources of supply and manufacturing are available.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"> During 2015 and 2014, there were no concentration of risks.</p> </div>
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.330 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.036 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Expiration Date
ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
2017-12-05
CY2015 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--11-30
CY2015 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2015 us-gaap Revenue Recognition Services Royalty Fees
RevenueRecognitionServicesRoyaltyFees
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>License and Royalty Agreements</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"> The Company has entered into licensing agreements with certain investors in various international markets in an attempt to capitalize on the Company&#x2019;s technology. The investors typically pay a licensing fee to receive Company marketing programs, technology and know-how in a selected area. The investor may be given a right to sell sub-license agreements as well. As part of the accounting for the up-front license fee paid, or payable, to the Company, revenue from the up-front license fee is recognized based on such factors as when the payment is due, collectability and when all material services or conditions relating to the sale have been substantially performed by the Company based on the terms of the agreement. The Company has twelve active licensing agreements. The following areas each have one license agreement: El Salvador, Guatemala, Panama, Honduras, China and Pakistan. The following areas each have two license agreements: India, Nicaragua and Costa Rica.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 8%"> In addition to the license fee, the Company earns processing and storage fees on subsequent processing and storage revenues received by the licensee in the licensed territory and a fee on any sub-license agreements that are sold by the licensee where applicable.&#xA0;These fees are included in processing and storage fees revenue on the consolidated statements of comprehensive income.&#xA0;As part of the accounting for royalty revenue from India, the Company uses estimates and judgments based on historical processing and storage volume in determining the timing and amount of royalty revenue to recognize.&#xA0;&#xA0;&#xA0;&#xA0;The Company periodically reviews license and royalty receivables for collectability and, if necessary, will record an expense for an allowance for uncollectible accounts.</p> </div>
CY2015 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Foreign
EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
0.188 pure
CY2015 dei Entity Registrant Name
EntityRegistrantName
CRYO CELL INTERNATIONAL INC
CY2015 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2015 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9795579 shares
CY2015 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
257972 shares
CY2015 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
1.70
CY2015 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Reclassification</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"> Certain reclassifications to Inventory and Intangible Assets have been made to prior period amounts in the Consolidated Balance Sheets and the Consolidated Statements of Cash Flows to conform to the current period presentation.&#xA0;These reclassifications had no effect on the previously reported current and total assets or liabilities, net income or cash flows from operating, investing and financing activities.</p> </div>
CY2015 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9537607 shares
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.90
CY2015 dei Document Period End Date
DocumentPeriodEndDate
2015-11-30
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0
CY2015 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"> The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period.&#xA0;Actual results could differ from those estimates.</p> </div>
CY2015 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.15 pure
CY2015 dei Trading Symbol
TradingSymbol
CCEL
CY2015 us-gaap Treasury Stock Acquired Repurchase Authorization
TreasuryStockAcquiredRepurchaseAuthorization
Open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission
CY2015 us-gaap Concentration Risk Supplier
ConcentrationRiskSupplier
Company depends on one supplier for the source of its collection kits
CY2015 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.85
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-8.952 pure
CY2015 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 Segments
CY2015 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
123633
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
108480
CY2015 us-gaap Net Income Loss
NetIncomeLoss
8106343
CY2015 us-gaap Allowance For Doubtful Accounts Receivable Recoveries
AllowanceForDoubtfulAccountsReceivableRecoveries
386198
CY2015 us-gaap Revenues
Revenues
21091431
CY2015 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
235292
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
69850
CY2015 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
3205435
CY2015 us-gaap License And Services Revenue
LicenseAndServicesRevenue
0
CY2015 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
19620138
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
2933224
CY2015 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-117231
CY2015 us-gaap Licenses Revenue
LicensesRevenue
1000000
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
22993
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1964879
CY2015 us-gaap Noncash Or Part Noncash Acquisition Debt Assumed1
NoncashOrPartNoncashAcquisitionDebtAssumed1
1300000
CY2015 us-gaap Income Tax Reconciliation Tax Credits Foreign
IncomeTaxReconciliationTaxCreditsForeign
150000
CY2015 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
375374
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-313936
CY2015 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
29008
CY2015 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-178935
CY2015 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
203
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
8276275
CY2015 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
169932
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
949521
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
621802
CY2015 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
423504
CY2015 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-18824
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
968345
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-7156822
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
602978
CY2015 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-6761000
CY2015 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-608000
CY2015 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
150000
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1480140
CY2015 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
269000
CY2015 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
260272
CY2015 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
3205435
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
872895
CY2015 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0
CY2015 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
264000
CY2015 us-gaap Interest Expense
InterestExpense
1303872
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-719349
CY2015 us-gaap Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
149000
CY2015 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2015 us-gaap Costs And Expenses
CostsAndExpenses
18158207
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-3259218
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45780
CY2015 us-gaap Cost Of Services
CostOfServices
5630865
CY2015 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
995716
CY2015 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-7369513
CY2015 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2015 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-540246
CY2015 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
63000
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
69850
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
603000
CY2015 us-gaap Advertising Expense
AdvertisingExpense
756000
CY2015 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2015 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
213000
CY2015 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
272000
CY2015 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
12389452
CY2015 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
23000
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
335709
CY2015 us-gaap Adjustment For Amortization
AdjustmentForAmortization
241208
CY2015 us-gaap Depreciation And Amortization
DepreciationAndAmortization
92110
CY2015 us-gaap Sponsor Fees
SponsorFees
7000
CY2015 us-gaap Depreciation
Depreciation
218000
CY2015 us-gaap Equity Method Investment Other Than Temporary Impairment
EquityMethodInvestmentOtherThanTemporaryImpairment
684000
CY2015 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
699682
CY2015 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2015 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
29000
CY2015 ccel Process And Storage Royalties
ProcessAndStorageRoyalties
1000000
CY2015 ccel Effective Income Tax Rate Reconciliation Valuation Allowances
EffectiveIncomeTaxRateReconciliationValuationAllowances
10.194 pure
CY2015 ccel Number Of Deliverables For Revenue Recognized
NumberOfDeliverablesForRevenueRecognized
2 Deliverables
CY2015 ccel Income Tax Reconciliation Permanent Disallowances
IncomeTaxReconciliationPermanentDisallowances
160000
CY2015 ccel Date Of Notification Received Related To Terminating License Agreement
DateOfNotificationReceivedRelatedToTerminatingLicenseAgreement
2011-08-19
CY2015 ccel Net Cash Proceeds From Sale Of Assets Percentage
NetCashProceedsFromSaleOfAssetsPercentage
0.50 pure
CY2015 ccel Exhibit Display Period
ExhibitDisplayPeriod
P5Y
CY2015 ccel Income Tax Reconciliation Foreign Tax Withholding
IncomeTaxReconciliationForeignTaxWithholding
150000
CY2015 ccel Payment To Participants Of Profit Sharing Agreement
PaymentToParticipantsOfProfitSharingAgreement
796759
CY2015 ccel Types Of License Agreements
TypesOfLicenseAgreements
2 Agreement
CY2015 ccel Defined Contribution Plan Employer Matching Contribution Amount
DefinedContributionPlanEmployerMatchingContributionAmount
114000
CY2015 ccel Deferred Revenue Recognition Period
DeferredRevenueRecognitionPeriod
P12M
CY2015 ccel Effective Income Tax Rate Reconciliation Permanent Disallowances
EffectiveIncomeTaxRateReconciliationPermanentDisallowances
0.200 pure
CY2015 ccel Share Based Compensation Shares Authorized Under Stock Option Plan Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlanExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm
P5Y4D
CY2015 ccel Associate Stock Purchase Plan Price Percentage Of Common Stock Market Price
AssociateStockPurchasePlanPricePercentageOfCommonStockMarketPrice
0.50 pure
CY2015 ccel Date Of Amendment Related To License Agreement
DateOfAmendmentRelatedToLicenseAgreement
2011-10-17
CY2015 ccel Number Of License Agreement
NumberOfLicenseAgreement
2 Agreement
CY2015 ccel Period For Doubtful Of Accounts Receivable Due From Client
PeriodForDoubtfulOfAccountsReceivableDueFromClient
P30D
CY2015 ccel Effective Income Tax Rate Foreign Tax Withholding
EffectiveIncomeTaxRateForeignTaxWithholding
0.188 pure
CY2015 ccel Product Revenue
ProductRevenue
471293
CY2015 ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
-11243
CY2015 ccel Number Of Licensing Agreement Made By Entity
NumberOfLicensingAgreementMadeByEntity
12 Agreement
CY2015 ccel Contracted Storage Period Option One
ContractedStoragePeriodOptionOne
P1Y
CY2015 ccel Contracted Storage Period Option Two
ContractedStoragePeriodOptionTwo
P21Y
CY2015 ccel Contracted Storage Period Option Three
ContractedStoragePeriodOptionThree
Lifetime
CY2015 ccel Asset Purchase Agreement Number Of Units To Be Sold
AssetPurchaseAgreementNumberOfUnitsToBeSold
4000 shares
CY2015 ccel Asset Purchase Agreement Per Unit Amount On Completion Of Sales Criteria
AssetPurchaseAgreementPerUnitAmountOnCompletionOfSalesCriteria
25
CY2015 ccel Increase Decrease In Prepaid Expenses In Connection With Acquisition
IncreaseDecreaseInPrepaidExpensesInConnectionWithAcquisition
-104000
CY2015 ccel Income Tax Reconciliation Valuation Allowance Release
IncomeTaxReconciliationValuationAllowanceRelease
8150000
CY2014Q2 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
26000

Files In Submission

Name View Source Status
0001193125-16-485790-index-headers.html Edgar Link pending
0001193125-16-485790-index.html Edgar Link pending
0001193125-16-485790.txt Edgar Link pending
0001193125-16-485790-xbrl.zip Edgar Link pending
ccel-20151130.xml Edgar Link completed
ccel-20151130.xsd Edgar Link pending
ccel-20151130_cal.xml Edgar Link unprocessable
ccel-20151130_def.xml Edgar Link unprocessable
ccel-20151130_lab.xml Edgar Link unprocessable
ccel-20151130_pre.xml Edgar Link unprocessable
d244143d10k.htm Edgar Link pending
d244143dex1039.htm Edgar Link pending
d244143dex311.htm Edgar Link pending
d244143dex312.htm Edgar Link pending
d244143dex313.htm Edgar Link pending
d244143dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending